AstraZeneca to build cancer cell therapy base in Shanghai for Asian markets

AstraZeneca on Thursday said it plans to build a cell therapy manufacturing and supply base in Shanghai. The project also provides for an innovation center, writes xrust. The implementation of the idea will make the company the first global drug manufacturer with a full range of capabilities in the field of cell therapy in China.

The British pharmaceutical company said in a statement on its Chinese social media account that the cell therapy manufacturing facility will be used to produce and supply CAR-T cell therapy to China and other Asian countries.

The essence of the method: CAR-T therapy modifies the patient's immune cells so that they recognize a specific target and destroy cancer cells.

An AstraZeneca spokesman told Reuters the cell therapy investment is part of the company's plan to invest $15 billion in China by 2030. This achieves the expansion of drug production and research development.

Despite AstraZeneca's significant investments in the United States, most notably through a $50 billion deal last year, the company continues to grow its business in its second-largest market.

Xrust AstraZeneca will build a cancer cell therapy base in Shanghai for Asian markets